Recent Updates
Recently added Catalysts
SEPN Positive Sentiment

Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

Tuesday, August 25, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Septerna, Inc. has appointed Dr. Rajiv Patni as Chief Medical Officer. Dr. Patni brings extensive experience in the biotechnology sector, which is expected to bolster Septerna's efforts in G protein-coupled receptor drug discovery. This strategic move aims to enhance the company's leadership and innovation in the field.

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of an experienced industry veteran.
  • Dr. Patni's expertise may enhance drug discovery efforts.
  • Strengthens leadership team at Septerna.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~70 mo
Minimal dilution risk
Lead asset
SEP-631
Phase 1 · Healthy Volunteers

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Rajiv Patni, M.D., as Chief Medical Officer. Dr.

Frequently Asked Questions

Who has been appointed as Chief Medical Officer at Septerna?

Dr. Rajiv Patni has been appointed as Chief Medical Officer at Septerna.

What is the focus of Septerna, Inc.?

Septerna focuses on G protein-coupled receptor drug discovery.

What is the significance of Dr. Patni's appointment?

Dr. Patni's experience is expected to enhance Septerna's drug discovery efforts.

ShareAdd on Google
Tags: SEPN Viatris Investor Conferences Healthcare Septerna Rajiv Patni Chief Medical Officer biotechnology G protein-coupled receptor
Last updated: Aug 25, 2026

Biotech snapshot

Cash runway
$517M liquidity · $7M/mo burn
~70 mo
Minimal dilution risk
Lead asset
SEP-631Phase 1
Healthy Volunteers →